Development Pipeline
We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 30 projects that we review regularly so that we can give priority to the most promising programs.
Pipeline Overview
The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development.
More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.
Number of programs in clinical development.
| Phase | Area | Program (Mode-of-action) | Indication | |
|---|---|---|---|---|
| III | ONC | Copanlisib (PI3K Inhibitor) |
Non-Hodgkin Lymphoma |  |
| III | ONC | Darolutamide (AR Inhibitor) |
Prostate Cancer (mHSPC) |
 |
| III | ONC | Darolutamide (AR Inhibitor) |
Adjuvant Prostate Cancer |  |
| III | ONC | Darolutamide (AR Inhibitor) |
Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy |
 |
| III | CVD | Finerenone (MR Antagonist) |
Heart Failure (HFmr/pEF) |
 |
| III | CVD | Finerenone (MR Antagonist) |
Non-diabetic CKD |  |
| III | CVD | Vericiguat (sGC Stimulator) |
Heart Failure (HFrEF) |
 |
| III | CVD | Asundexian (FXIa Inhibitor) |
Stroke Prevention in Atrial Fibrillation Insight Story Link |
 |
| III | CVD | Asundexian (FXIa Inhibitor) |
2⁰ Stroke Prevention (OCEANIC Stroke) |
 |
| III | Other | Elinzanetant (Neurokinin-1,3 Rec Antag.) |
Vasomotor Symptoms |  |
| III | Other | Aflibercept 8mg (VEGF Inhibitor) |
Retinal Vein Occlusion (QUASAR) |
 |
| III | Other | Gadoquatrane (High Relaxivity Contrast Agent) |
Magnetic Resonance Imaging (HRCA-PAT) |
 |
| II | ONC | Regorafenib (combi Nivolumab) |
Solid tumors (recurrent or metastatic) |
 |
| II | CVD | Asundexian (FXIa Inhibitor) |
Major Adverse Cardiac Events Prevention Insight Story Link |
 |
| II | IM | Zabedosertib (IRAK4 Inhibitor) |
Atopic Dermatitis (DAMASK) |
 |
| II | Other | Runcaciguat (sGC Activator) |
Non-prolif. Diabetic Retinopathy (NPDR) |
 |
| I | ONC | Elimusertib (ATR Inhibitor) |
Advanced solid tumors, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma |
 |
| I | ONC | AhR Inhibitor | Advanced solid tumors Insight Story Link |
 |
| I | ONC | mEGFR Inhibitor | Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation |
 |
| I | ONC | DGKzeta Inhibitor | Advanced solid tumors |  |
| I | ONC | CCR8 Ab | Advanced solid tumors |  |
|
I |
ONC | VVD Keap1 Act | Cancer |  |
| I | CVD | Congestive Heart Failure rAAV Gene Therapy |
Congestive Heart Failure |  |
| I | CVD | sGC Activator Oral | Chronic Kidney Disease |  |
| I | CVD | Anti-a2AP | Acute Ischemic Stroke; Pulmonary Embolism |
 |
| I | CVD | sGC Activator Inhale | Acute Respiratory Distress Syndrome |
 |
| I | CVD | SEMA 3a | Alport Syndrome |  |
| I | NRD | Bemdaneprocel (Parkinson’s Disease Cell Therapy) |
Parkinson's Disease |  |
| I | NRD | Parkinson‘s Disease rAAV Gene Therapy |
Parkinson’s Disease |  |
| I | NRD | Multiple System Atrophy rAAV Gene Therapy |
Multiple System Atrophy |
|
| I | NRD | Pompe Disease rAAV Gene Therapy |
Pompe Disease | |
| I | NRD | Huntington‘s Disease rAAV Gene Therapy |
Huntington‘s Disease | |
| I | NRD | LGMD2I/R9 rAAV Gene Therapy |
Limb Girdle Muscular Dystrophy |
|
| I | Other | GPR84 Antagonist | Diabetic Neuropathic Pain |
 |
| 0* | ONC | DGKalpha Inhibitor | Cancer |  |
| 0* | ONC | PSMA TAC | Advanced Prostate Cancer |  |
| 0* | ONC | PSMA SMOL TAC | Advanced Prostate Cancer | |
| 0* | ONC | VVD STAT3 Inh | Cancer |  |
| 0* | CVD | Anti-coagulant | Anti-coagulation |  |
| 0* | Other | Next Generation Liver MRI |
Contrast Media |  |
* Including Precision Cardiovascular, Nephrology & Acute Care
New molecular entity
Life cycle management
